Published on March 19, 2010 at 7:32 AM
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that one
abstract has been accepted for presentation at the National Kidney
Foundation (NKF) 2010 Spring Clinical Meeting being held April 13-17,
2010 in Orlando, FL. The full abstract can now be viewed on the NKF
website at http://www.kidney.org/news/meetings/clinical/index.cfm.
“Aspects of IV Ferumoxytol Administration and Acute Adverse Events in
CKD Patients”
The following abstract will be presented:
-
“Aspects of IV Ferumoxytol Administration and Acute Adverse Events in
CKD Patients” (Sharma et al). Poster presentation; 6:00 pm – 7:30 pm,
Wednesday, April 14. Using pooled data from 3 pivotal studies in
patients with iron deficiency anemia and CKD, both on and not on
dialysis, the analyses evaluated the safety of 510 mg ferumoxytol by
injection number and interval between injections. The results of the
analyses support that the safety profile of ferumoxytol is comparable
between first and second administration regardless of the number of
days in between the administrations.
Source AMAG Pharmaceuticals, Inc.
fb80cfa1-b539-4b22-9c30-43832203c7da|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anemia, Cancer, Constipation, Dialysis, Diarrhea, Edema, Hypersensitivity, Iron Deficiency, Kidney Disease, Nausea, Ultrasound